WHO ICTRP trial
Specified drug use-results survey of TALVEY Subcutaneous Injection in patients…
JPRN-UMIN000059272 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000059272 |
|---|---|
| Public title | Specified drug use-results survey of TALVEY Subcutaneous Injection in patients with relapsed or refractory multiple myeloma |
| Scientific title | Specified drug use-results survey of TALVEY Subcutaneous Injection in patients with relapsed or refractory multiple myeloma - TAL1L |
| Primary sponsor | Janssen Pharmaceutical K.K. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Observational |
| Phase | Not selected |
| Countries | Japan |
| Conditions | relapsed or refractory multiple myeloma |
| Registration date | Jan 12, 2025 |
| Target size | 100 |
| Registry page | center6.umin.ac.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: